Zomig (Zolmitriptan) Patent Expiration, LOE Window & CMS Spending

Zomig (Zolmitriptan) by Amneal Pharmaceuticals: Off-Patent Genericized (AB Competition), 10 AB generics, $470K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmneal Pharmaceuticals
FDA Application & PathwayN021450 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$470K
2024 Medicare Part D Spend$255K
2024 Medicaid Spend$215K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 16.4% 2-yr change)